Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW685698X in Pediatric Perennial Allergic Rhinitis
NCT01622231Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2012
- Primary completion
- Nov 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluticasone in perennial allergic rhinitis (PAR), sponsored by GSK. Primary endpoint: Adverse Events at 13 weeks. Started Jun 2012; status: completed.
02
Drugs
fluticasone
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01622231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01622231.